Skip to content

Genome vs Transcriptome vs Proteome: What Each Layer Measures

Oak
Three versions of the same feathered creature on a dark plinth: a stone cast, a glowing vapor form, and a living animal.

The genome is the sequence you were born with, it is effectively identical in every nucleated cell, and it does not change with sleep, diet, or a flu. The transcriptome is the set of RNA molecules present in a specific sample at the moment it was drawn, and it changes on a timescale of minutes to hours. The proteome is the set of proteins present and doing work. That depends on transcription plus translation rate, plus folding, plus degradation. If you want one sentence: the genome tells you what is possible, the transcriptome tells you what was being requested, and the proteome tells you what was built. The three layers are measured with different instruments and produce different file formats. They carry different error modes, and they agree with each other far less than the central dogma would suggest.

What each layer physically is, and what an assay returns

Whole-genome sequencing (WGS) reads the roughly 3.1 billion base pairs of your diploid genome. At 30x mean coverage on a short-read instrument you get about 100 GB of raw reads, aligned into a BAM or CRAM file, then reduced to a VCF (variant call format) file of about 4 to 5 million single-nucleotide variants and roughly 500,000 to 700,000 small insertions and deletions relative to the reference. That VCF is a static asset. Sequence it again in ten years and, barring somatic mutation and sequencing error, you get the same answer.

RNA sequencing (RNA-seq) measures transcript abundance. In practice you get 20 to 50 million paired reads per sample from whole blood. The output is a counts matrix with genes or transcripts as rows and one column per sample, holding integers or estimated fragment counts. Abundance spans about five orders of magnitude, and in whole blood the globin and immunoglobulin transcripts can eat a large fraction of your reads unless they are depleted. The transcriptome is a snapshot and behaves like one. Whether a sample was drawn at 7am or 7pm shifts hundreds of genes.

Proteomics measures peptides. It does not measure proteins directly. Mass spectrometry digests proteins with trypsin and separates peptides by liquid chromatography. It then measures mass-to-charge ratios and infers protein identity from the fragment spectra. Affinity methods take a different route and use antibodies or aptamers to quantify a fixed panel of targets. Either way the output is a matrix of relative intensities, usually log-transformed, with far fewer features than RNA-seq: hundreds to a few thousand plasma proteins rather than 15,000 to 20,000 expressed genes. These are complementary technologies with different biases, and reviews of the omics toolkit treat them as distinct measurement families rather than interchangeable views of the same thing.12

Why mRNA level does not predict protein level

This is the single most useful thing to internalize before you start analyzing your own data. Across studies, the correlation between transcript abundance and protein abundance for the same gene in the same sample is moderate at best. The reasons are mechanical. Translation initiation rates differ by orders of magnitude between messages. Protein half-lives range from minutes to days, while mRNA half-lives cluster in hours. Post-translational modification, secretion, and complex assembly all change what the mass spectrometer sees without changing the transcript count at all.

The practical consequence is that transcript and protein measurements answer different questions, and integrating them requires deliberate method rather than a join on gene ID. Work on combining transcriptome and proteome profiling makes this explicit. The two data types are integrated to resolve discrepancies and to improve confidence in protein identification. The reason is not that one validates the other.3 Proteotranscriptomic approaches go further and use RNA-seq to build a sample-specific search database for the mass spectrometry step, which recovers peptides that a generic reference proteome would miss.4

We think the correct mental model is a series of filters. The genome constrains the sequence space of possible proteins. The transcriptome narrows that to what is being expressed in this tissue at this hour. The proteome reports the surviving output after translation and degradation. A signal that appears at all three layers is worth much more than a signal at one.

Where each layer earns its keep

Use the genome for anything that is time-invariant. Pharmacogenes are the clearest case: your CYP2C19, CYP2D6, DPYD, and TPMT star alleles are fixed, and the annotation is well standardized. Carrier status and HLA type live here, as do polygenic scores and rare variants of clinical interest. Any variant that a clinician would act on should be confirmed in an accredited clinical laboratory before it informs care, and interpretation belongs with a genetic counselor or physician.

Use the transcriptome for state. It is the layer that responds to infection and training load, as well as sleep debt and inflammation. A single RNA-seq sample is close to useless for a healthy person, because you have no personal baseline to compare it against. Four to six samples across a year, drawn at a consistent time of day, gives you a distribution and makes deviations interpretable.

Use the proteome for the things that circulate and do the work. Plasma proteins integrate signals from many tissues, and many of them are the direct analytes clinicians already use, such as CRP, albumin, and apolipoprotein B. Proteomics extends that familiar panel by two or three orders of magnitude in feature count.

The strongest demonstrations of multi-layer value come from rare disease. In cohorts of suspected inborn errors of metabolism, adding RNA-seq and proteomics to an unsolved exome or genome raises diagnostic yield by showing functional consequences of variants that sequence alone cannot classify.5 A variant of uncertain significance becomes interpretable when RNA-seq shows aberrant splicing of that transcript and proteomics shows the corresponding protein is absent. This is functional evidence, produced by measurement rather than prediction.

A concrete pipeline for each layer

For the genome, align with bwa-mem2 or dragen-os to GRCh38 with alt contigs handled properly, then call small variants with DeepVariant or GATK HaplotypeCaller. Store as CRAM with the reference recorded, since CRAM cuts storage roughly threefold versus BAM. Annotate with Ensembl VEP or bcftools csq, and keep the raw VCF separate from every annotated derivative. Structural variants need a separate caller such as Manta or Delly, and short reads will miss a meaningful fraction of them regardless.

For the transcriptome, quantify with salmon quant -l A --validateMappings --gcBias --seqBias against a decoy-aware index, or use STAR plus featureCounts if you need alignments for splicing work. Import with tximport, then run differential expression with DESeq2 on raw counts and never on TPMs. Keep RIN (RNA integrity number) and library size for every sample, because degradation drives a 3’ bias that mimics real biology.

For proteomics, mass spectrometry data arrives as vendor files converted to mzML. Those are then searched with MSFragger, DIA-NN, or MaxQuant. Expect 30 to 60 percent missingness across features in plasma. Decide your missingness policy before you look at results, and log-transform before any distance or correlation calculation. Batch effects in proteomics are larger than in RNA-seq, so randomize sample order and keep a pooled reference in every batch.

The thread that connects all three is annotation discipline. Systems biology pitches omics as a route from parts lists to mechanism, and that only works if identifiers, versions, and reference builds are recorded at every step.6 Half of the reproducibility failures we see are gene ID mapping errors. They do not come from biology.

Questions people also ask

Does the genome change over time? For practical purposes, no. Germline sequence is stable, so a single high-quality WGS is a permanent asset. Somatic mutation accumulates in tissues, and clonal hematopoiesis in blood can become detectable with age, but this requires deep sequencing to see and is not what a standard 30x genome reports.

Which layer should I measure first? The genome, because it is one-time and cheap per unit of information, and permanently reusable. Then add repeated transcriptome and proteome samples, since those only become interpretable against your own baseline.

Why does proteomics report so few features compared to RNA-seq? Dynamic range. Plasma protein concentrations span more than ten orders of magnitude, albumin dominates by mass, and no current method samples the low-abundance tail deeply from a small volume. RNA-seq has a far narrower dynamic range and an amplification step, so it covers its feature space more evenly.

Can I skip RNA-seq and just do proteomics? You lose splicing information, non-coding RNA, and the ability to build a sample-specific search database that improves peptide identification.4 Also, many transcriptional responses resolve before protein levels move, so RNA catches faster dynamics.

What about the metabolome? It sits downstream of the proteome and reflects enzyme activity plus diet and microbiome input. Standard descriptions of the omics stack place it as the layer closest to phenotype and the most environmentally sensitive.7 It complements the three layers here rather than replacing any of them.

Footnotes

  1. Richard P Horgan, Louise C Kenny. ‘Omic’ technologies: genomics, transcriptomics, proteomics and metabolomics. The Obstetrician & Gynaecologist, 2011. https://doi.org/10.1576/toag.13.3.189.27672 ↩

  2. Bensu Karahalil. Overview of Systems Biology and Omics Technologies. Current Medicinal Chemistry, 2016. https://doi.org/10.2174/0929867323666160926150617 ↩

  3. Dhirendra Kumar, Gourja Bansal, Ankita Narang, et al. Integrating transcriptome and proteome profiling: Strategies and applications. PROTEOMICS, 2016. https://doi.org/10.1002/pmic.201600140 ↩

  4. Michal Levin, Falk Butter. Proteotranscriptomics – A facilitator in omics research. Computational and Structural Biotechnology Journal, 2022. https://doi.org/10.1016/j.csbj.2022.07.007 ↩ ↩2

  5. Sarah L. Stenton, Laura S. Kremer, Robert Kopajtich, et al. The diagnosis of inborn errors of metabolism by an integrative “multi‐omics” approach: A perspective encompassing genomics, transcriptomics, and proteomics. Journal of Inherited Metabolic Disease, 2019. https://doi.org/10.1002/jimd.12130 ↩

  6. Mario Vailati-Riboni, Valentino Palombo, Juan J. Loor. What Are Omics Sciences?. Periparturient Diseases of Dairy Cows, 2017. https://doi.org/10.1007/978-3-319-43033-1_1 ↩

  7. Devendra Singh, Neelam Geat, Motilal Mehriya, et al. Omics (Genomics, Proteomics, Metabolomics, Etc.) Tools to Study the Environmental Microbiome and Bioremediation. Waste to Energy: Prospects and Applications, 2020. https://doi.org/10.1007/978-981-33-4347-4_10 ↩

Pothos builds longitudinal molecular profiles of individuals: whole-genome sequencing, single-cell RNA sequencing, and plasma proteomics, delivered as a detailed report, every data file, and stored cells. Build your profile.